Why the study?
Do nonacetylated salicylates have fewer adverse effects than aspirin or NSAIDs in patients with arthritic disease?
Do nonacetylated salicylates have fewer adverse effects than aspirin or NSAIDs in patients with arthritic disease?
Nonacetylated salicylates may warrant greater consideration as first-line therapy for arthritis due to a more favorable side effect profile compared to aspirin and NSAIDs.
May support consideration in aspirin-intolerant arthritis patients; leaves open need for randomized confirmation of safety advantage.
Despite the adverse effects of aspirin, many physicians still consider it to be the drug of choice for initial treatment of arthritic disorders. Nonsteroidal antiinflammatory drugs (NSAIDs) are better tolerated than aspirin but have similar, although milder, side effects. The nonacetylated salicylates appear to have fewer adverse effects than either aspirin or the NSAIDs and therefore may warrant greater consideration as first-line therapy for arthritis.
No takes yet. Share an insight, caveat, or question.
Roy D. Altman (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: